Cargando…

Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting

OBJECTIVES: Quick and inexpensive SARS-CoV-2 screening and frontline testing are in growing demand. Our study aimed to evaluate the performance of the immunochromatographic AMP rapid antigen test (AMP RAT) compared to the gold-standard real-time reverse transcription PCR (rRT-PCR) in a hospital coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Leixner, Georg, Voill-Glaninger, Astrid, Bonner, Elisabeth, Kreil, Anna, Zadnikar, René, Viveiros, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168346/
https://www.ncbi.nlm.nih.gov/pubmed/34087486
http://dx.doi.org/10.1016/j.ijid.2021.05.063
_version_ 1783701869560856576
author Leixner, Georg
Voill-Glaninger, Astrid
Bonner, Elisabeth
Kreil, Anna
Zadnikar, René
Viveiros, André
author_facet Leixner, Georg
Voill-Glaninger, Astrid
Bonner, Elisabeth
Kreil, Anna
Zadnikar, René
Viveiros, André
author_sort Leixner, Georg
collection PubMed
description OBJECTIVES: Quick and inexpensive SARS-CoV-2 screening and frontline testing are in growing demand. Our study aimed to evaluate the performance of the immunochromatographic AMP rapid antigen test (AMP RAT) compared to the gold-standard real-time reverse transcription PCR (rRT-PCR) in a hospital cohort. METHODS: A total of 392 patients, who presented consecutively with COVID-19 symptoms in our emergency department, were included in this retrospective study. Two swabs were collected per patient: a nasopharyngeal for the RAT and a combined naso- and oropharyngeal for the rRT-PCR. A positive rRT-PCR (defined as cycle threshold (Ct) < 40) was found in 94 (24%) patients. RESULTS: In our cohort with a median patient age of 70, overall sensitivity and specificity of the AMP RAT was 69.2% (58.8–78.3, 95% CI) and 99.7% (98.1–100.0, 95% CI), respectively. In patients with a Ct value < 25 and < 30, higher sensitivities of 100.0% (89.4–100.0, 95% CI) and 91.8% (81.9–97.3%, 95% CI) were observed. CONCLUSIONS: The AMP RAT showed a high sensitivity in patients with a Ct value < 25 and < 30 and might be helpful for frontline testing whenever rRT-PCR is not readily available.
format Online
Article
Text
id pubmed-8168346
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-81683462021-06-01 Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting Leixner, Georg Voill-Glaninger, Astrid Bonner, Elisabeth Kreil, Anna Zadnikar, René Viveiros, André Int J Infect Dis Article OBJECTIVES: Quick and inexpensive SARS-CoV-2 screening and frontline testing are in growing demand. Our study aimed to evaluate the performance of the immunochromatographic AMP rapid antigen test (AMP RAT) compared to the gold-standard real-time reverse transcription PCR (rRT-PCR) in a hospital cohort. METHODS: A total of 392 patients, who presented consecutively with COVID-19 symptoms in our emergency department, were included in this retrospective study. Two swabs were collected per patient: a nasopharyngeal for the RAT and a combined naso- and oropharyngeal for the rRT-PCR. A positive rRT-PCR (defined as cycle threshold (Ct) < 40) was found in 94 (24%) patients. RESULTS: In our cohort with a median patient age of 70, overall sensitivity and specificity of the AMP RAT was 69.2% (58.8–78.3, 95% CI) and 99.7% (98.1–100.0, 95% CI), respectively. In patients with a Ct value < 25 and < 30, higher sensitivities of 100.0% (89.4–100.0, 95% CI) and 91.8% (81.9–97.3%, 95% CI) were observed. CONCLUSIONS: The AMP RAT showed a high sensitivity in patients with a Ct value < 25 and < 30 and might be helpful for frontline testing whenever rRT-PCR is not readily available. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-07 2021-06-01 /pmc/articles/PMC8168346/ /pubmed/34087486 http://dx.doi.org/10.1016/j.ijid.2021.05.063 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Leixner, Georg
Voill-Glaninger, Astrid
Bonner, Elisabeth
Kreil, Anna
Zadnikar, René
Viveiros, André
Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting
title Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting
title_full Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting
title_fullStr Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting
title_full_unstemmed Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting
title_short Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital setting
title_sort evaluation of the amp sars-cov-2 rapid antigen test in a hospital setting
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168346/
https://www.ncbi.nlm.nih.gov/pubmed/34087486
http://dx.doi.org/10.1016/j.ijid.2021.05.063
work_keys_str_mv AT leixnergeorg evaluationoftheampsarscov2rapidantigentestinahospitalsetting
AT voillglaningerastrid evaluationoftheampsarscov2rapidantigentestinahospitalsetting
AT bonnerelisabeth evaluationoftheampsarscov2rapidantigentestinahospitalsetting
AT kreilanna evaluationoftheampsarscov2rapidantigentestinahospitalsetting
AT zadnikarrene evaluationoftheampsarscov2rapidantigentestinahospitalsetting
AT viveirosandre evaluationoftheampsarscov2rapidantigentestinahospitalsetting